Rhythm Pharmaceuticals (STU:1RV) 3-Year Book Growth Rate : -8.80% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Rhythm Pharmaceuticals 3-Year Book Growth Rate?

Rhythm Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €0.93.

During the past 12 months, Rhythm Pharmaceuticals's average Book Value per Share Growth Rate was -73.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -8.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was -13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Rhythm Pharmaceuticals was -7.60% per year. The lowest was -10.80% per year. And the median was -9.35% per year.

Competitive Comparison of Rhythm Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Rhythm Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's 3-Year Book Growth Rate falls into.

Rhythm Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Rhythm Pharmaceuticals (STU:1RV) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Rhythm Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals (STU:1RV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (STU:1RV) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

RYTM:USA RYTM:Mexico

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

http://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Rhythm Pharmaceuticals (STU:1RV) Headlines

No Headlines